Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Exercise Training in Pregnancy for Obese Mothers

Exercise Training in Pregnancy. Good for the Mother - Good for the Child?

Observational studies demonstrate that overweight in pregnancy is a risk factor for adverse pregnancy outcomes as fetal macrosomia, prolonged labor, low Apgar score, shoulder dystocia, nerve plexus injuries, increased proportion of instrumental deliveries and perineal ruptures. There is a 2.6 fold risk for gestational diabetes mellitus (fourfold in morbidly obese women) and a recent study has shown that fetuses of obese mothers develop insulin resistance in uterus.

Main aims of this study are to assess if regular exercise in pregnancy among obese women can prevent or influence weight gain; impaired cardiac function in mother and fetus/newborn; impaired vascular function in mother; insulin resistance/sensitivity; body composition in mother and offspring; lumbopelvic pain; urinary and/or fecal incontinence; prolonged labor

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Women with a self-reported pre-pregnancy BMI of 28 or more will be eligible for our study. Woman are eligible if they are 18 years or older, with a singleton live fetus at an early (week 12-14) ultrasound scan. Exclusion criteria are pregnancy complications with high risk for preterm labour or diseases that could interfere with participation.

Primary outcome measure is weight increase based on weight measured at 14 weeks and immediately before labour. Assessments are done at baseline at 14 (12-18) weeks of pregnancy, and again in week 38, as well as 3 months postpartum. Some measurements are also done at other points in time. The maternal secondary outcome measurements include fasting glucose, glucose tolerance assessed by 2-h, 75 mg per-oral glucose tolerance test, insulin resistance assessed by HOMA-IR, weight, height, body composition estimated by skinfold measurements in pregnancy and by dual energy x-ray absorptiometry postpartum, blood markers, lumbopelvic pain, urin- and fecal incontinence, quality of life, psychological wellbeing, depression, and diet.

Studietype

Intervensjonell

Registrering (Faktiske)

91

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Trondheim, Norge, 7489
        • Norwegian University of Science and Technology

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Pre-pregnancy body mass index of 28 or more
  • 18 years or more
  • singleton live fetus at the routine ultrasound scan

Exclusion Criteria:

  • high risk for preterm labor or diseases that could interfere with participation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Exercise training
Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
Exercise training at the hospital
Andre navn:
  • Opplæring
Ingen inngripen: Control
Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Weight gain during pregnancy
Tidsramme: From 14 weeks pregnancy to delivery
Measured in kg
From 14 weeks pregnancy to delivery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fasting glucose
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Blood samples to determine the fasting glucose after an overnight fast (>10 hours)
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Glucose tolerance
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
2 hour 75 mg per-oral glucose tolerance test. Gestational diabetes is diagnosed as fasting glucose = or > 6.9 mmol/L or 2h concentration = or > 7.8 mmol/L.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Insulin resistance
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Homeostasis model assessment (HOMA-IR)
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Body composition
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Skinfold measurements, done by an experienced investigator using Harpenden kaliper. At the 3 months postpartum testing, also dual energy x-ray absorptiometry (DEXA scan) will be used.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Blood markers for cardiovascular disease
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Inflammation markers, cytokines (leptin, resistin, adiponectin, tnf-alfa). Blood will be collected and stored for later analyses.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Lumbopelvic pain
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Clinical assessment (active straight leg raising, pelvic provocation test), and validated questionnaire.
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Urin- and fecal incontinence
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Pelvic floor muscle function will be assessed by clinical assessment and by 2D and 3D ultrasound. The prevalence and severity of urin- and fecal incontinence will also be assessed by a validated questionnaire
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Quality of life
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Validated questionnaire
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Sleep
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Epworth sleepiness scale
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Physical activity
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Level of physical activity will be assessed by activity registration (armbands) and by validated questionnaires
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Diet
Tidsramme: From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Validated questionnaire: Norkost
From 14 weeks pregnancy to 38 weeks pregnancy and also at 3 months postpartum
Offspring birth weight, length and head circumference
Tidsramme: At delivery
As recorded by the hospital
At delivery
Delivery complications
Tidsramme: At delivery
Vaginal or caesarean delivery, and recorded complications during the delivery
At delivery
Markers of inflammation and metabolism in cord blood
Tidsramme: At delivery
Cord blood will be sampled and stored for later analysis of relevant markers of inflammation and metabolism (including resistin, leptin, adiponectin)
At delivery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. september 2010

Primær fullføring (Faktiske)

1. juni 2015

Studiet fullført (Faktiske)

1. juni 2016

Datoer for studieregistrering

Først innsendt

6. september 2010

Først innsendt som oppfylte QC-kriteriene

17. november 2010

Først lagt ut (Anslag)

18. november 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. januar 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. januar 2020

Sist bekreftet

1. juni 2018

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ETiP-Ob

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .